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Since December 2019, a type of novel coronavirus (CoV) infection, later named severe acute respiratory syndrome--CoV 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses, broke out in Wuhan, Hubei, China.[@bib0001], [@bib0002], [@bib0003] The virus targets the airway epithelium using angiotensin-converting enzyme 2 (ACE2) as a receptor and causes a novel CoV-related pneumonia. Some severe cases develop into acute respiratory distress syndrome (ARDS), which can be fatal.[@bib0004] The infection spread throughout China and worldwide within 2 months. As of February 25, 2020, a report from the World Health Organization indicated a total of 81,109 lab-confirmed cases from 38 countries and regions. Of those, China had more than 78,000 cases, and deaths had exceeded 2,700.[@bib0005]

Current epidemiologic evidence suggested that SARS-CoV-2 was highly contagious and humans were generally susceptible.[@bib0006] Although most of the cases were mild or moderate and the patients recovered after proper treatment, patients with underlying morbidities carried a substantially higher mortality than those without, especially those with cardiovascular disease. Also, severe cases can develop complications other than respiratory syndromes, and reports suggest that 7% to 12% of the patients experience acute cardiac damage.[@bib0002] ^,^ [@bib0007]

Solid organ transplantation recipients, including heart transplant (HTx) recipients, have a higher infection risk than the normal population because of immunosuppression by anti-rejection therapy.[@bib0008] ^,^ [@bib0009] However, epidemiologic and clinical characteristics of HTx recipients during the SARS-CoV-2 epidemic are largely unknown so far. We designed a comprehensive questionnaire to collect exposure history, clinical manifestations, and treatments of HTx recipients in our hospital.

Methods {#sec0001}
=======

All patients receiving an allograft heart transplantation and discharged between July 2015 and January 2020 in our hospital were included in this retrospective, single-center study and numbered from 1 to 87 by date of transplantation. We obtained personal information, transplantation-related history, epidemiologic history, clinical manifestations, and treatments through a web-based comprehensive questionnaire designed by clinical physicians and public health experts. The missing or unclear data collected from the questionnaire were reconciled by direct communication with the patients or their close relatives. The latest laboratory data of the recipients within the last 2 months were extracted from the hospital database. All data were finally checked and confirmed by 2 independent investigators. This study was approved by the ethics committee of Renmin Hospital of Wuhan University. Our study complies with the International Society for Heart and Lung Transplantation ethics statement.

Continuous variables were expressed as mean (standard deviation) if they were normally distributed or median (interquartile range) if they were not. Categorical variables were expressed as count and frequency. All statistical analyses were performed using SPSS software, version 26.0.

Results {#sec0002}
=======

Demographic data {#sec0003}
----------------

A total of 87 recipients were included in the study and carefully followed up ([Table 1](#tbl0001){ref-type="table"} ). There were 63 men and 24 women, the average age was 51 ± 12 years, 80 (92.0%) of them lived together with relatives, and the number of relatives ranged from 1 to 8. A total of 83 (95.4%) recipients followed the pre-defined anti-rejection therapy, and there were no rejection episodes in the past 2 months, whereas 2 patients were admitted to the hospital because of bacterial infection and subsequently discharged after proper antibiotic treatment. The accompanying comorbidities in this group include hypertension (28 cases, 32.2%), hyperlipidemia (15 cases, 17.2%), diabetes (20 cases, 23.0%), new onset coronary heart disease (1 case, 1.1%), chronic obstructive pulmonary disease (1 case, 1.1%), cerebral vascular disease (6 cases, 6.9%), chronic renal dysfunction (8 cases, 12.6%), gout (6 cases, 6.9%), and hypothyroidism (1 case, 1.1%). All recipients with comorbidities were prescribed with corresponding drugs by specifically trained physicians.Table 1Demographic Description of the Heart Transplant RecipientsTable 1DemographicRecipients (N = 87)Age, years Mean ± SD51 ± 12 Range14--73Sex Male63 (72.4%) Female24 (27.6%)Living together with relatives80 (92.0%)Anti-rejection therapy compliance83 (95.4%)Comorbidity Hypertension28 (32.2%) Hyperlipidemia15 (17.2%) Diabetes20 (23.0%) New onset CHD1 (1.1%) COPD1 (1.1%) Cerebrovascular disease6 (6.9%) Renal dysfunction11 (12.6%) Gout6 (6.9%) Hypothyroidism1 (1.1%)[^2][^3]

Epidemiologic and exposure history {#sec0004}
----------------------------------

A total of 79 recipients lived in Hubei Province, whereas 57 recipients had a Wuhan contact-related history. The whole group reported no obvious contact with patients with confirmed or suspected SARS-CoV-2--associated disease COVID-19. Protective procedures were initiated with 11 of 16 recipients (68.8%) who were in contact with asymptomatic individuals who traveled to or came back from Wuhan. After January 23, 2020, 84 of 87 recipients (96.6%) undertook precautionary procedures in their community. Of these 87 recipients, 56 (64.4%) self-quarantined at home by more than 1 week. The other major exposure history is presented in [Table 2](#tbl0002){ref-type="table"} .Table 2Exposure History of the RecipientsTable 2Exposure historyRecipients (N = 87)Have been to Wuhan57 (65.5%)Contact with 2019-nCoV patients0 (0.0%)Contact with asymptomatic individual with epidemic history16 (18.4%) Precautionary procedure11/16 (68.8%)Take public transport25 (28.7%) Precautionary procedure24/25 (96.0%)Have been to crowded place19 (21.8%) Precautionary procedure18/19 (94.7%)Attend group events5 (5.7%) Precautionary procedure3/5 (60.0%)Animal or poultry touch16 (18.4%) Animal death0/16 (0.0%)Precautionary procedure in the family84 (96.6%) Mask71/84 (84.5%) Hand wash75/84 (89.3%) Sanitization52/84 (61.9%)Precautionary procedure in the community84 (96.6%) Daily body temperature and symptoms monitoring63/84 (75.0%) Unified living supplies purchasing and distribution59/84 (70.2%) Community shutting down and no passing72/84 (85.7%)Self-quarantine at home56 (64.4%) 22--28 days52/56 (92.9%) 15--21 days3/56 (5.4%) 8--14 days1/56 (1.8%)[^4][^5]

Laboratory results {#sec0005}
------------------

Laboratory results of 47 recipients within the last 2 months were identified and extracted from the database, including blood routine, tacrolimus concentration, and liver and kidney function examination ([Table 3](#tbl0003){ref-type="table"} ). The average white blood cell count was 7.2 ± 2.2 × 10^9^ cells/liter, and 6 (6 of 47, 12.8%) recipients had an abnormal white blood cell count, including 5 that were elevated. The average neutrophil percentage was 60.4% ± 12.1%, 5 recipients were abnormal. The average lymphocyte percentage was 27.7% ± 9.9%, although 10 (10 of 47, 21.3%) recipients had lymphopenia and 31 (31 of 47, 66.0%) recipients had a lymphocyte percentage lower than 30%. The average tacrolimus concentration was 7.6 ± 2.4 ng/ml, which was therapeutic. Examination of liver and renal function was evaluated by alanine aminotransferase, aspartate aminotransferase, urea, and creatinine assessments, and the average results were grossly normal, although 5 and 6 recipients had liver or kidney insufficiency, respectively.Table 3Laboratory Results of the RecipientsTable 3Lab resultRecipients (N = 47)Blood routine WBC count (× 10^9^ cells/liter)7.2 ± 2.2 Abnormal WBC count6 (12.8%) Neu%60.4 ± 12.1 Abnormal Neu%5 (10.6%) Lym%27.7 ± 9.9 \<20%10 (21.3%) 20%--30%21 (44.7%) 30%--40%10 (21.3%) 40%--50%5 (10.6%) \>50%1 (2.1%)FK506, ng/ml7.6 ± 2.4 \<5.04 (8.5%) 5.0--7.925 (53.2%) 8.0--11.916 (34.0%) ≥12.02 (4.3%)Biochemistry ALT, U/liter22.6 ± 17.8 AST, U/liter25.5 ± 18.7 Abnormal ALT or AST5 (10.6%) Urea, mmol/liter8.6 ± 3.0 Cr, µmol/liter92.9 ± 38.4 Abnormal Urea or Cr6 (12.8%)[^6][^7]

Clinical characteristics of recipients with airway infection {#sec0006}
------------------------------------------------------------

There were 4 upper airway infections reported during this time period ([Table 4](#tbl0004){ref-type="table"} ). Three of them were tested for SARS-CoV-2 infection and were negative. The other recipient with an upper airway infection recovered after 6 days and was not tested for SARS-CoV-2 because the specific test kit had not yet launched during the early stage of the SARS-CoV-2 epidemic. All of them were tested for influenza A and B, and 1 upper airway infection recipient was confirmed with influenza A infection. All 4 recipients successfully recovered after proper therapies.Table 4Clinical Characteristics of the Recipients with Airway InfectionTable 4Patient numberDate of onsetSymptomBlood routineTest for airway pathogenChest CT reportDiagnosisTreatmentOutcome17December 31, 2019Nasal obstructionWBC 11.34 × 10^9^, Neu% 71.6%, Lym% 18.7%SARS-Cov-2 (N/A), FluA (−), FluB (−)NegativeUpper airway infectionAntibioticsRecovered44January 28, 2020Fever, nasal obstructionWBC 6.36 × 10^9^, Neu% 76.4%, Lym% 13.9%SARS-Cov-2 (−), FluA (+), FluB(−)NegativeUpper airway infection; FluAAntibiotics, anti-viral drugsRecovered58February 2, \`2020Dry coughWBC 5.3 × 10^9^, Neu% 89.5%, Lym% 5.7%SARS-Cov-2 (−), FluA (−), FluB (−), HPIV (−), RSV (−), Adv (−), Mpn (−), Cpn(−)Viral pneumoniaLower airway infection,\
viral pneumoniaAntibiotics, anti-viral drugsRecovered70January 19, 2020FeverWBC 4.3 × 10^9^, Neu% 74.7%, Lym% 12.3%SARS-Cov-2 (−), FluA (−), FluB (−), HPIV (−), RSV (−), Adv (−), Mpn (−), Cpn(−)Pulmonary infectionLower airway infection,\
pulmonary infectionAntibioticsRecovered[^8]

Discussion {#sec0007}
==========

This is the largest comprehensive report of HTx recipients during the SARS-CoV-2 epidemic, and our findings indicated that this immunocompromised population received similar exposure, including contact with individuals with travel from Wuhan, taking public transport, and going to crowded places; however, they exhibited less infection than expected.

The origins of this virus have been traced back to the seafood wholesale market in Wuhan, China.[@bib0004] In our epidemiologic investigation, 16 recipients experienced contact with animals or poultry, but there was no reported animal death. No recipients have ever been to the seafood wholesale market in Wuhan or were in contact with any potential supply chains of wild or game meat.

SARS-CoV-2 mainly spreads through the respiratory tract, and survival time of SARS-CoV-2 in air may be somewhat limited. Any protective measures that block the transmission pathway can reduce the risk of infection. According to our investigation of epidemiologic history, it would be reasonable to infer that although HTx recipients have a similar epidemiologic history to the normal population, they may have a better protection awareness and use of precautions as a usual practice during the SARS-CoV-2 epidemic.

Studies have shown that people are generally susceptible to CoV. CoVs such as SARS-CoV and Middle East respiratory syndrome (MERS)-CoV also caused severe lower respiratory tract infection with ARDS, extrapulmonary manifestations, and multiorgan dysfunction syndrome among both immunocompetent and immunocompromised hosts, with mortality rates of 10% and 35%, respectively.[@bib0010] ^,^ [@bib0011] Early patient reports from SARS-CoV-2 find similar trends. Severe manifestations, even death, with SARS-CoV-2 have been associated in elderly patients with comorbidities, including hypertension, diabetes, and heart and/or kidney disease.[@bib0003] This finding is similar to increased severity and death in elderly patients following both SARS and MERS-CoV infection.[@bib0012] ^,^ [@bib0013] For the MERS-CoV outbreak, smoking, hypertension, diabetes, cardiovascular disease, and/or other chronic illnesses were present in most deaths and correspond to findings in animal models.[@bib0014] The accompanying comorbidities in this group of HTx recipients include hypertension (28 cases, 34.2%), hyperlipidemia (15 cases, 17.2%), diabetes (20 cases, 23.0%), new onset coronary heart disease (1 case, 1.1%), chronic obstructive pulmonary disease (1 case, 1.1%), cerebrovascular disease (6 cases, 6.9%), chronic renal dysfunction (11 cases, 12.6%), hyperuricemia (6 cases, 6.9%), and hypothyroidism (1 case, 1.1%), and the average age is 50.5 ± 11.7 years. Thus, it would indicate that vigilance is necessary for these immunocompromised recipients following SARS-CoV-2 infection.

Our results are unexpected because only 4 recipients got airway infection and 3 of them had a negative SARS-CoV-2 result. This is similar to the information from the Organ Transplant Center in our hospital, where only 2 cases were reported with SARS-CoV-2 infection in renal transplantation.[@bib0015] Data from Ju et al.[@bib0016] suggest that the number of solid organ transplantation recipients in China suffering from SARS-CoV-2 infection are few, including only 9 confirmed cases altogether. With limited data, it is difficult to determine the populations that may be most susceptible to SARS-CoV-2. More data are needed to determine the susceptibility of the immunocompromised population.

CoVs are positive-strand RNA viruses, which primarily target mucosal surfaces of respiratory and intestinal tracts to establish an infection.[@bib0017] ^,^ [@bib0018] Epithelial cell surface components are exploited as primary receptors to mediate viral entry and the establishment of a viral infection.[@bib0019] One integral protease of the renin-angiotensin system (RAS), ACE2, which is a major physiologic regulator of the cardiovascular system, facilitates cellular entry of human CoVs.[@bib0020] ^,^ [@bib0021] Recently, ACE2 had been identified as a receptor for SARS-CoV-2.[@bib0022] ^,^ [@bib0023] ACE2 is thought to be a key regulator in maintenance of RAS homeostasis.[@bib0024] ^,^ [@bib0025] Several studies illustrate the possible mechanism of immunosuppressants in activating RAS.[@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030] Ferrario et al.[@bib0031] demonstrated that the treatment of cultured astrocytes with angiotensin-II caused a marked reduction in neural ACE2 mRNA and protein, mediated with either losartan or both losartan and lisinopril by the AT1 receptor. It is unclear what, if any, difference in the expression of pulmonary ACE2 exists in the presence of immunosuppression, and investigating the difference in ACE2 between the recipients and the normal population would provide further evidence.

Similar to SARS-CoV and MERS-CoV infection, patients with SARS-CoV-2 infections exhibit symptoms of viral pneumonia, including fever, cough, or dyspnea, and bilateral lung infiltration in severe cases. All these 3 CoVs induce excessive and aberrant non-effective host immune responses that are associated with severe lung pathology, leading to death.[@bib0032] The autopsy results of deceased patients indicate diffuse alveolar damage with alveolar edema, focal hemorrhage, and hyaline membrane formation,[@bib0033] which are similar to the pathologic manifestations of ARDS.[@bib0034] However, most SARS-CoV-2 infections were mild or moderate cases; meanwhile, case reports showed that the clinical manifestations and progression of SARS-CoV-2 infection in renal transplant recipients were generally consistent with common SARS-CoV-2 infected patients.[@bib0015] According to our investigation of epidemiologic history, we could not deny the possibility of contacting and getting infected with SARS-CoV-2 in HTx recipients. It is important to note that laboratory data may be misleading in HTx recipients because several of our patients already exhibited lymphopenia, which may be a result of the use of immunosuppressants that prevent lymphocyte development and proinflammatory cytokines gene expression, such as IL-2, IL-3, IL-4, interferon-γ, and tumor necrosis factor-α.[@bib0035], [@bib0036], [@bib0037], [@bib0038] Glucocorticoids inhibit immune responses by negatively regulating immunocytes[@bib0039], [@bib0040], [@bib0041], [@bib0042], [@bib0043], [@bib0044] and especially weaken the strength of the T-cell receptor signal, which is important in T-cell activation and differentiation.[@bib0045] Thus, we imply that if HTx recipients are infected with SARS-CoV-2, they may not exhibit typical manifestations in the early stage because of the presence of immunosuppression. Our data suggest that maintaining the blood trough concentration of FK506 at 7.9 ± 2.9 ng/ml is appropriate. However, the appropriate degree of immunosuppression needs further verification.

There are several limitations in this study. First, the detailed clinical data for the recipients with airway symptoms were not fully extracted because of the variation of the database in different hospitals. Second, it is reported that SARS-CoV-2 may have an extremely long incubation time, so longer observation and follow up are warranted. Furthermore, a larger sample size will contribute to greater reliability of the data. Furthermore, recall bias, which would be hard to avoid in a survey-based investigation, should also be noted as a limitation.

In conclusion, according to our investigation, we suggest that HTx recipients who used enhanced protection measures during the SARS-CoV-2 outbreak did not have a substantially higher rate of infection among the population. It is also important to note that immunosuppressed patients may not exhibit typical manifestations and might present confusing laboratory data, thus obfuscating diagnosis in some cases. These early data will require confirmation as the pandemic establishes around the world.
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